Literature DB >> 21325653

Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.

J Koivunen1, N Scheinin, J R Virta, S Aalto, T Vahlberg, K Någren, S Helin, R Parkkola, M Viitanen, J O Rinne.   

Abstract

BACKGROUND: Patients with amnestic mild cognitive impairment (MCI) have greater risk of conversion to Alzheimer disease (AD). Increased brain amyloid burden in AD and MCI has been demonstrated with PET using [(11)C] Pittsburgh compound B (PiB) as a tracer.
OBJECTIVE: To evaluate change in β-amyloid deposition in with MCI during 2-year follow-up.
METHODS: Patients with MCI and controls were studied with [(11)C] PiB PET, MRI, and neuropsychometry at baseline and these investigations were repeated in patients with MCI after follow-up.
RESULTS: Those patients with MCI converting to AD during follow-up had greater [(11)C] PiB retention in the posterior cingulate (p=0.020), in the lateral frontal cortex (p=0.006), in the temporal cortex (p=0.022), in the putamen (p=0.041), and in the caudate nucleus (p=0.025) as compared to nonconverters. In converters, there was no significant change in [(11)C] PiB uptake, whereas an increase was seen as compared to baseline in nonconverters in the anterior and posterior cingulate, temporal and parietal cortices, and putamen. Hippocampal atrophy was greater in converters at baseline than in nonconverters, but increased significantly in both groups during follow-up.
CONCLUSIONS: Hippocampal atrophy and amyloid deposition seem to dissociate during the evolution of MCI, the atrophy increasing clearly and [(11)C] PiB retention changing modestly when conversion to AD occurs. Longer follow-up is needed to determine whether nonconverters would convert to AD later, which would suggest accelerated [(11)C] PiB retention preceding clinical conversion.
© 2011 by AAN Enterprises, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21325653     DOI: 10.1212/WNL.0b013e318212015e

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  62 in total

1.  Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia.

Authors:  John C Morris
Journal:  Arch Neurol       Date:  2012-06

Review 2.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

3.  Functional connectivity variations in mild cognitive impairment: associations with cognitive function.

Authors:  S Duke Han; Konstantinos Arfanakis; Debra A Fleischman; Sue E Leurgans; Elizabeth R Tuminello; Emily C Edmonds; David A Bennett
Journal:  J Int Neuropsychol Soc       Date:  2011-10-18       Impact factor: 2.892

4.  [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment.

Authors:  A Brück; J R Virta; J Koivunen; J Koikkalainen; N M Scheinin; H Helenius; K Någren; S Helin; R Parkkola; M Viitanen; J O Rinne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-06-26       Impact factor: 9.236

5.  In vivo characterization of the early states of the amyloid-beta network.

Authors:  Jorge Sepulcre; Mert R Sabuncu; Alex Becker; Reisa Sperling; Keith A Johnson
Journal:  Brain       Date:  2013-07       Impact factor: 13.501

6.  Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease.

Authors:  Stefan Teipel; Helmut Heinsen; Edson Amaro; Lea T Grinberg; Bernd Krause; Michel Grothe
Journal:  Neurobiol Aging       Date:  2013-10-28       Impact factor: 4.673

7.  Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.

Authors:  David A Wolk; Carl Sadowsky; Beth Safirstein; Juha O Rinne; Ranjan Duara; Richard Perry; Marc Agronin; Jose Gamez; Jiong Shi; Adrian Ivanoiu; Lennart Minthon; Zuzana Walker; Steen Hasselbalch; Clive Holmes; Marwan Sabbagh; Marilyn Albert; Adam Fleisher; Paul Loughlin; Eric Triau; Kirk Frey; Peter Høgh; Andrea Bozoki; Roger Bullock; Eric Salmon; Gillian Farrar; Christopher J Buckley; Michelle Zanette; Paul F Sherwin; Andrea Cherubini; Fraser Inglis
Journal:  JAMA Neurol       Date:  2018-09-01       Impact factor: 18.302

Review 8.  Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases.

Authors:  Eugene M Cilento; Lorrain Jin; Tessandra Stewart; Min Shi; Lifu Sheng; Jing Zhang
Journal:  J Neurochem       Date:  2019-01-31       Impact factor: 5.372

9.  Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.

Authors:  Rik Ossenkoppele; Nelleke Tolboom; Jessica C Foster-Dingley; Sofie F Adriaanse; Ronald Boellaard; Maqsood Yaqub; Albert D Windhorst; Frederik Barkhof; Adriaan A Lammertsma; Philip Scheltens; Wiesje M van der Flier; Bart N M van Berckel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-23       Impact factor: 9.236

Review 10.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.